Loading...
Tirzepatide
Add to Wishlist
Dual GIP/GLP-1 Receptor Agonist — Advanced Metabolic Research Compound
In Stock
Select Size
$60.00$72.00
You Save
$12.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
Tirzepatide is a 39-amino acid dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist with a C20 fatty diacid modification at Lys20 that enables albumin binding and a pharmacokinetic half-life of approximately 5 days, supporting once-weekly dosing. The peptide backbone is based on the native GIP sequence with engineered GLP-1 receptor cross-reactivity, creating an imbalanced dual agonist with approximately 5-fold greater GIP receptor potency relative to its GLP-1 activity. The SURMOUNT-1 clinical trial published in the New England Journal of Medicine demonstrated mean body weight reductions of 20.9-22.5% over 72 weeks at the 10-15mg weekly doses — the largest weight reductions reported for any single-agent pharmacotherapy at the time of publication. GIP receptor activation on pancreatic beta cells potentiates glucose-dependent insulin secretion, while GLP-1 receptor engagement provides appetite suppression, delayed gastric emptying, and additional incretin effects. Tirzepatide shares its mechanism of action with the FDA-approved products Mounjaro and Zepbound, though this PEPCELL product is a research-grade compound manufactured for laboratory investigation, not an FDA-approved pharmaceutical. Active research is investigating tirzepatide's effects on NASH, heart failure with preserved ejection fraction, and obstructive sleep apnea.
Handling & Storage
Published research protocols reference weekly subcutaneous administration. Store refrigerated at 2-8°C. Consult applicable literature for specific research applications.
Published Research Protocols
Published research protocols reference a titration schedule starting at 2.5mg weekly with incremental increases every 4 weeks up to 15mg. Consult applicable literature for specific research applications.
Research Applications
Dual Receptor Activation
Simultaneously activates GIP and GLP-1 receptors through a single peptide molecule with approximately 5-fold greater GIP potency relative to GLP-1 activity. This imbalanced dual agonism distinguishes tirzepatide from both pure GLP-1 agonists and balanced dual agonists, with GIP receptor engagement providing beta-cell insulin potentiation and potential adipose tissue remodeling effects.
Initial effects within first month
Research Studies
Superior Weight Reduction
The SURMOUNT-1 trial (n=2,539) demonstrated mean body weight reductions of 20.9% (10mg) and 22.5% (15mg) over 72 weeks — the largest reductions observed for any single-agent compound in controlled clinical research at the time. Over one-third of participants in the highest dose group achieved weight reductions exceeding 25% of baseline body weight.
Initial effects within first month
Research Studies
Glycemic Control
The SURPASS clinical trial program demonstrated HbA1c reductions of 2.0-2.6 percentage points across dose groups in subjects with type 2 diabetes, with up to 97% of participants achieving HbA1c below 7.0%. These glycemic improvements exceeded those observed with comparator GLP-1 agonists in head-to-head studies.
Initial effects within first month
Research Studies
Frequently Asked Questions
How does this Tirzepatide relate to Mounjaro or Zepbound?
Tirzepatide is the same active peptide molecule found in FDA-approved Mounjaro (for type 2 diabetes) and Zepbound (for weight management). However, this PEPCELL product is a research-grade compound manufactured for laboratory investigation and is not an FDA-approved pharmaceutical. It is not manufactured by Eli Lilly and is not a substitute for prescribed medications.
Why does Tirzepatide target GIP receptors in addition to GLP-1?
GIP receptor activation on pancreatic beta cells potentiates glucose-dependent insulin secretion through a signaling pathway complementary to GLP-1. Research also suggests GIP signaling may promote adipose tissue remodeling and improve lipid handling. The dual agonism produces larger metabolic effects than GLP-1 activation alone, as demonstrated in head-to-head clinical trials where tirzepatide outperformed semaglutide.
How should research-grade Tirzepatide be reconstituted?
Reconstitute lyophilized tirzepatide with bacteriostatic water, injecting slowly along the vial wall. The C20 fatty diacid acylation provides excellent solution stability. Do not shake — gentle swirling is acceptable. After reconstitution, store at 2-8°C and use within 30 days.
What purity testing does PEPCELL perform on Tirzepatide?
Each tirzepatide batch undergoes independent HPLC purity analysis and mass spectrometry identity verification at Janoshik Analytical Laboratory. Current batches test at 99.9% purity — our highest-purity metabolic peptide. Batch-specific Certificates of Analysis are available for every lot.
Is this Tirzepatide product for human use?
This research-grade tirzepatide is sold exclusively for in-vitro research, laboratory investigation, and educational purposes. It is not an FDA-approved drug product, is not manufactured to pharmaceutical GMP standards, and is not intended for human consumption or self-administration. Individuals seeking tirzepatide for medical use should consult a physician about FDA-approved options.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to Tirzepatide
Research13 min read
Metabolic Research Peptides: Semaglutide vs Tirzepatide vs Retatrutide
A comparative analysis of single, dual, and triple incretin receptor agonists in metabolic research, examining mechanism differences, published clinical data, and structural innovations driving this rapidly evolving field.
Dr. James ParkResearch Analyst
Research12 min read
Semaglutide: A Comprehensive Research Guide to GLP-1 Receptor Agonists
An in-depth exploration of semaglutide research, covering its development history, GLP-1 receptor mechanism, pharmacokinetics, and how it compares to other incretin-based peptides in published studies.
Dr. James ParkResearch Analyst
